Vivifrail Exercise Program in Nonagenarians: Effects on Function, Muscle, and Cognition (Vivifrail)
Effects of a Multicomponent Exercise Program Based on the Vivifrail Protocol on Functional Capacity, Muscle Morphology, and Cognition in Nonagenarians: A Randomized Clinical Trial
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
This is a three-arm, parallel-group randomized controlled trial evaluating a home-based multicomponent exercise program based on the Vivifrail protocol in community-dwelling nonagenarians (aged 90 years or older). A total of 54 participants (18 per group) will be randomly allocated to one of three groups: G1, performing the Vivifrail program at least twice a week; G2, performing it at least three times a week; or a control group (GC) maintaining usual activities.
Randomization will be performed using Randomizer software (www.randomizer.org) by an independent researcher not involved in the assessments. Allocation is stratified by sex and by baseline functional level, defined by collapsing the six Vivifrail functional categories into two groups (lower function: Types A, B, and B+; higher function: Types C, C+, and D), to ensure balanced distribution of baseline physical function across the three groups. Each participant is still assigned the individualized Vivifrail training passport corresponding to their specific functional category. Given the autonomous, home-based nature of the intervention, participants and interventionists cannot be blinded; however, outcome assessors remain blinded to group allocation throughout the study.
Assessments occur at three timepoints: baseline (T0), 12 weeks (T1), and 24 weeks (T2). The 24-week intervention is individualized according to each participant's functional profile, determined by the Short Physical Performance Battery (SPPB) and the corresponding Vivifrail training passport.
The primary outcome is physical function measured by the total SPPB score (0-12). Secondary outcomes include mobility (Timed Up and Go and cognitive dual-task cost), handgrip strength, lower-limb power (five-times sit-to-stand with linear encoder), gait speed, balance, muscle morphology of the vastus lateralis (ultrasound), cognition (Mini-Mental State Examination), and change in Vivifrail functional category. Data will be analyzed by intention to treat using generalized estimating equations (GEE), examining the group-by-time interaction.
Tipo de estudo
Inscrição (Estimado)
Estágio
- Não aplicável
Contactos e Locais
Locais de estudo
-
-
Rio Grande do Sul
-
Porto Alegre, Rio Grande do Sul, Brasil, 90035-903
- Hospital de Clínicas de Porto Alegre (HCPA) - Geriatrics outpatient clinic
-
Porto Alegre, Rio Grande do Sul, Brasil, 90690-200
- Escola de Educação Física, Fisioterapia e Dança (ESEFID/UFRGS) - and participants' homes
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
- Adulto mais velho
Aceita Voluntários Saudáveis
Descrição
Inclusion Criteria:
- Aged 90 years or older
- Living in the community (own or family home)
- Able to walk independently or with a walking aid (cane or walker), without third-party assistance
- Minimum cognitive capacity to understand and perform the exercises (MMSE, education-adjusted cutoffs)
- Adequate home conditions to perform the program
- Availability of a family member or caregiver to support the sessions
- Signed informed consent (with legal guardian assistance when needed)
Exclusion Criteria:
- - Total inability to walk or permanent bedridden condition
- Severe cognitive impairment preventing safe understanding and execution of exercises
- Severe orthopedic, neurological, or rheumatological conditions preventing exercise
- Concurrent participation in another structured exercise program
- Anticipated unavailability (relocation, planned hospitalization, or institutionalization) during the intervention
- Refusal to sign informed consent or absence of a legal guardian when required
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Solteiro
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Vivifrail - 2 sessions/week (G1)
Home-based Vivifrail multicomponent exercise program performed at least twice a week for 24 weeks, individualized by functional profile (SPPB and Vivifrail passport).
|
Individualized multicomponent home-based training (strength/power, balance, gait, and flexibility) prescribed according to the participant's Vivifrail functional profile.
|
|
Experimental: Vivifrail - 3 sessions/week (G2)
Home-based Vivifrail multicomponent exercise program performed at least three times a week for 24 weeks, individualized by functional profile.
|
Individualized multicomponent home-based training (strength/power, balance, gait, and flexibility) prescribed according to the participant's Vivifrail functional profile.
|
|
Sem intervenção: Control (GC)
Participants maintain usual activities without a structured exercise program during the 24-week period.
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Change in physical function measured by the Short Physical Performance Battery (SPPB) total score
Prazo: Baseline (T0), 12 weeks (T1), and 24 weeks (T2)
|
Total SPPB score ranging from 0 to 12 points (higher scores indicate better lower-extremity physical function), combining balance, gait speed, and chair-stand tests.
|
Baseline (T0), 12 weeks (T1), and 24 weeks (T2)
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Mobility - Timed Up and Go (TUG)
Prazo: Baseline (T0), 12 weeks (T1), and 24 weeks (T2)
|
ime in seconds to rise, walk 3 meters, turn, return, and sit.
|
Baseline (T0), 12 weeks (T1), and 24 weeks (T2)
|
|
Mobility under dual task - Cognitive TUG and dual-task cost (DTC%) ·
Prazo: Baseline (T0), 12 weeks (T1), and 24 weeks (T2)).
|
TUG performed with a concurrent cognitive task; dual-task cost calculated as percentage change relative to single-task TUG.
|
Baseline (T0), 12 weeks (T1), and 24 weeks (T2)).
|
|
Handgrip strength
Prazo: Baseline (T0), 12 weeks (T1), and 24 weeks (T2)).
|
Maximal isometric handgrip strength in kilograms, measured with a Jamar dynamometer.
|
Baseline (T0), 12 weeks (T1), and 24 weeks (T2)).
|
|
Lower-limb muscle power - Five-times sit-to-stand
Prazo: Baseline (T0), 12 weeks (T1), and 24 weeks (T2)).
|
ime in seconds and estimated lower-limb power measured during the five-times sit-to-stand test using a linear encoder.
|
Baseline (T0), 12 weeks (T1), and 24 weeks (T2)).
|
|
Gait speed
Prazo: aseline (T0), 12 weeks (T1), and 24 weeks (T2)).
|
Usual gait speed in meters per second.
|
aseline (T0), 12 weeks (T1), and 24 weeks (T2)).
|
|
Balance
Prazo: Baseline (T0), 12 weeks (T1), and 24 weeks (T2)).
|
Static balance assessed by the SPPB balance component (side-by-side, semi-tandem, and tandem stands).
|
Baseline (T0), 12 weeks (T1), and 24 weeks (T2)).
|
|
Change in Vastus Lateralis Muscle Thickness
Prazo: Baseline (T0), 12 weeks (T1), and 24 weeks (T2)
|
Vastus lateralis muscle thickness measured by B-mode ultrasound, defined as the distance between the adipose-muscle and muscle-bone interfaces, analyzed in ImageJ by a single trained, blinded assessor.
|
Baseline (T0), 12 weeks (T1), and 24 weeks (T2)
|
|
Change in Vastus Lateralis Echo Intensity (Muscle Quality)
Prazo: Baseline (T0), 12 weeks (T1), and 24 weeks (T2)
|
Muscle quality assessed by echo intensity on B-mode ultrasound, expressed in arbitrary units (grayscale, 0-255) via manual region-of-interest analysis in ImageJ, excluding fascia and bone.
Higher echo intensity indicates greater intramuscular fat/fibrous infiltration, i.e., poorer muscle quality.
Single assessor blinded to group allocation.
|
Baseline (T0), 12 weeks (T1), and 24 weeks (T2)
|
|
Cognition - Mini-Mental State Examination (MMSE)
Prazo: Baseline (T0), 12 weeks (T1), and 24 weeks (T2)
|
Global cognitive function measured by the MMSE, using education-adjusted cutoffs.
|
Baseline (T0), 12 weeks (T1), and 24 weeks (T2)
|
|
Change in Vivifrail functional category
Prazo: Baseline (T0), 12 weeks (T1), and 24 weeks (T2)
|
Transition across Vivifrail functional categories (Types A, B, B+, C, C+, D) over the intervention period.
|
Baseline (T0), 12 weeks (T1), and 24 weeks (T2)
|
Colaboradores e Investigadores
Patrocinador
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- 79748517.5.0000.5347
- U1111-1343-8083 (Outro identificador: WHO Universal Trial Number (UTN))
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .